ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on February 17, 2017, covering events that occurred on February 14, 2017. The filing addresses Item 5.02 regarding the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation awards and board fee adjustments.
Material Changes and Compensation Awards
On February 14, 2017, the Board of Directors approved cash bonuses and stock option grants for 2016 performance for the following Named Executive Officers:
- Adam S. Grossman (President, CEO, Director): $86,250 cash bonus and 55,000 stock options.
- Dr. James Mond (EVP, CSO, CMO): $55,612 cash bonus and 22,500 stock options.
- Brian Lenz (VP, CFO): $86,556 cash bonus and 22,500 stock options.
Additionally, the Board approved a 3% increase to the annual cash fees paid to non-executive Board members.
Terms of Stock Options
- Grant Date: February 14, 2017.
- Exercise Price: $5.00 per share (based on the closing price on the grant date).
- Vesting Schedule: 25% vests on the one-year anniversary of the grant date; the remaining 75% vests monthly in equal installments over the subsequent three years.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, risk factors, or management commentary beyond the specific compensation approvals detailed above.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 100,000 new options granted.
- Confirm the current market price of ADMA common stock relative to the $5.00 exercise price.
- Review the company's cash position to ensure the ability to fund the approximately $228,418 in total cash bonuses.
- Check subsequent filings for any changes to the vesting schedule or exercise price due to corporate actions.